Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033868 | 0.90 | POLB (0.53) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| Hydrochloric Acid SCHEMBL18130662 | 0.88 | POLB (0.56) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| SCHEMBL18768921 | 0.86 | POLB (0.59) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| SCHEMBL1566745 | 0.86 | POLB (0.64) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| SCHEMBL375074 | 0.86 | POLB (0.47) | POLBSSTR3OPRL1SIGMAR1OPRM1 | |
| SCHEMBL18742079 | 0.85 | POLB (0.62) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| SCHEMBL18768922 | 0.85 | POLB (0.62) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| SCHEMBL18768842 | 0.85 | POLB (0.62) | POLBPRMT5WDR77SSTR3SLC6A2 | |
| SCHEMBL1566841 | 0.82 | POLB (0.46) | POLBPRMT5WDR77SSTR3CCR2 | |
| SCHEMBL4980744 | 0.82 | PRMT5 (0.64) | POLBPRMT5WDR77SSTR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | POLB 3019/4885PRMT5 2082/4885WDR77 3409/4885 |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | POLB 3388/4885PRMT5 1793/4885WDR77 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.